SR One Capital Management LP Has $132.13 Million Stake in CRISPR Therapeutics AG $CRSP

SR One Capital Management LP lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) by 94.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,038,763 shares of the company’s stock after acquiring an additional 989,812 shares during the period. CRISPR Therapeutics makes up approximately 19.1% of SR One Capital Management LP’s investment portfolio, making the stock its 2nd largest position. SR One Capital Management LP’s holdings in CRISPR Therapeutics were worth $132,132,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of CRSP. Orbis Allan Gray Ltd boosted its holdings in CRISPR Therapeutics by 76.9% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,764,532 shares of the company’s stock valued at $134,467,000 after purchasing an additional 1,201,600 shares during the period. Geode Capital Management LLC raised its position in shares of CRISPR Therapeutics by 98.1% in the second quarter. Geode Capital Management LLC now owns 2,071,883 shares of the company’s stock valued at $100,789,000 after buying an additional 1,025,979 shares in the last quarter. State Street Corp grew its position in CRISPR Therapeutics by 35.6% during the second quarter. State Street Corp now owns 3,270,596 shares of the company’s stock worth $159,082,000 after buying an additional 859,334 shares in the last quarter. Norges Bank bought a new position in CRISPR Therapeutics during the 2nd quarter worth $19,772,000. Finally, Jump Financial LLC acquired a new position in CRISPR Therapeutics in the 2nd quarter valued at $17,331,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of CRISPR Therapeutics in a research report on Wednesday, January 21st. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research note on Saturday, February 14th. Citizens Jmp dropped their target price on shares of CRISPR Therapeutics from $86.00 to $80.00 and set a “market outperform” rating for the company in a research report on Friday, January 30th. Robert W. Baird cut their price target on shares of CRISPR Therapeutics from $52.00 to $44.00 and set a “neutral” rating for the company in a report on Tuesday, November 11th. Finally, Needham & Company LLC lifted their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a “buy” rating in a research note on Friday, February 13th. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, CRISPR Therapeutics currently has an average rating of “Hold” and an average price target of $64.24.

CRISPR Therapeutics Trading Down 4.5%

Shares of NASDAQ CRSP opened at $57.33 on Friday. The company has a market cap of $5.50 billion, a price-to-earnings ratio of -8.79 and a beta of 1.72. CRISPR Therapeutics AG has a 12 month low of $30.04 and a 12 month high of $78.48. The stock has a 50-day moving average price of $54.20 and a two-hundred day moving average price of $57.31.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.22). The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s revenue for the quarter was down 97.8% on a year-over-year basis. During the same quarter in the previous year, the business posted ($1.01) earnings per share. On average, sell-side analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 6,967 shares of the firm’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total transaction of $366,324.86. Following the sale, the chief executive officer owned 226,106 shares of the company’s stock, valued at $11,888,653.48. This trade represents a 2.99% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel James R. Kasinger sold 2,112 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the sale, the general counsel owned 85,115 shares in the company, valued at $4,475,346.70. This represents a 2.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 99,079 shares of company stock worth $5,643,674. Insiders own 4.30% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.